Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs.

ABSTRACT:

Objective

The study assessed persistence rates of biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis in Japan and compared resource utilization and treatment costs between persistence and non-persistence groups.

Methods

Data were extracted from a Japanese claims database between 2009 and 2015. bDMARD-naïve patients were identified and included in the final analysis. Survival analysis was used to estimate 1-year persistence rates for current bDMARDs. Propensity score matching was applied to control for potential treatment selection bias. Resource utilization and healthcare costs were calculated 1 year before and after initiation of bDMARDs and compared between persistence and non-persistence groups.

Results

A total of 6

SUBMITTER: Sruamsiri R 

PROVIDER: S-EPMC6119169 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature